STERIS Raises Dividend to $0.63 per share

Rhea-AI Summary

STERIS (NYSE: STE) has announced a quarterly dividend increase to $0.63 per share, marking a $0.06 increase from the previous dividend. This represents the company's 20th consecutive year of dividend growth. The dividend will be payable on September 26, 2025, to shareholders of record as of September 4, 2025.

STERIS, a leading global provider of products and services supporting patient care with a focus on infection prevention, continues to demonstrate its commitment to shareholder returns through consistent dividend growth. The company helps create a healthier and safer world by providing innovative healthcare and life science solutions globally.

Positive

• Increased quarterly dividend by $0.06 to $0.63 per share
• Achieved 20 consecutive years of dividend growth
• Demonstrates strong financial position and commitment to shareholder returns

Negative

• High debt levels may limit financial flexibility
• Faces potential risks from increasing competition and pricing pressures
• Exposed to economic downturn risks and international market uncertainties

Insights

Dividend Policy Analyst

STERIS's 10.5% dividend increase signals financial strength and shareholder commitment after 20 consecutive years of dividend growth.

STERIS has announced a 10.5% increase to its quarterly dividend, raising it from $0.57 to $0.63 per share. This $0.06 boost marks the company's 20th consecutive year of dividend growth, positioning STERIS among the elite group of consistent dividend growers in the healthcare sector.

This two-decade streak of uninterrupted dividend increases demonstrates exceptional financial stability and a shareholder-friendly capital allocation policy. For context, only about 65 companies in the S&P 500 have achieved 20+ years of consecutive dividend increases, placing STERIS in the top tier of dividend reliability.

The size of this increase (10.5%) significantly outpaces the current U.S. inflation rate, representing a meaningful boost in real returns for income-focused investors. This above-inflation increase signals management's confidence in future cash flow generation and overall business stability.

The dividend payout demonstrates STERIS's balanced approach to capital allocation - reinvesting in growth while maintaining its commitment to returning capital to shareholders. For income-focused portfolios, this reliability creates a compelling case for STERIS as a defensive healthcare holding with consistent yield expansion.

With STERIS's core business in infection prevention and healthcare sterilization services providing relatively stable cash flows regardless of economic conditions, this dividend trajectory appears sustainable, backed by the company's essential role in healthcare infrastructure.

DUBLIN, IRELAND, July 30, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that the Company will distribute a quarterly interim dividend of $0.63 per share. This represents a $0.06 increase in the dividend and the Company’s 20^th consecutive year of dividend growth. The dividend is payable on September 26, 2025, to shareholders of record at the close of business on September 4, 2025.  

Additional information about the U.S. tax treatment of dividends, including required Forms 8937, is available at www.steris-ir.com.

STERIS is a leading global provider of products and services that support patient care with an emphasis on infection prevention. WE HELP OUR CUSTOMERS CREATE A HEALTHIER AND SAFER WORLD by providing innovative healthcare and life science products and services around the globe.

Company Contact:

Julie Winter, Vice President, Investor Relations and Corporate Communications

Julie_Winter@steris.com

+1.440.392.7245

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION

This release may contain statements concerning certain trends, expectations, forecasts, estimates, or other forward-looking information affecting or relating to STERIS or its industry, products or activities that are intended to qualify for the protections afforded “forward-looking statements” under the Private Securities Litigation Reform Act of 1995 and other laws and regulations. Forward-looking statements speak only as to the date the statement is made and may be identified by the use of forward-looking terms such as “may,” “will,” “expects,” “believes,” “anticipates,” “plans,” “estimates,” “projects,” “targets,” “forecasts,” “outlook,” “impact,” “potential,” “confidence,” “improve,” “optimistic,” “deliver,” “orders,” “backlog,” “comfortable,” “trend,” and “seeks,” or the negative of such terms or other variations on such terms or comparable terminology.

Many factors could cause actual results to differ materially from those in the forward-looking statements including, without limitation, those identified in STERIS’s recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Other potential risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements include, without limitation: (a) operating costs, pressure on pricing (including, without limitation, as a result of inflation), Customer loss and business disruption (including, without limitation, difficulties in maintaining relationships with employees, Customers, clients or suppliers) being greater than expected and leading to erosion of profit margins; (b) STERIS’s ability to successfully integrate acquired businesses into its existing businesses, including unknown or inestimable liabilities, impairments, or increases in expected integration costs or difficulties in connection with the integration of such businesses; (c) changes in tax laws or interpretations or the adoption of certain income tax treaties in jurisdictions where we operate that could increase our consolidated tax liabilities, including changes in tax laws that would result in STERIS being treated as a domestic corporation for United States federal tax purposes, or tariffs and/or other trade barriers; (d) the possibility that compliance with laws, court rulings, certifications, regulations, or other regulatory actions, or the outcome of any pending or threatened litigation, including the Isomedix litigation, may delay, limit or prevent new product or service introductions, impact production, supply and/or marketing of existing products or services, result in uncovered costs, or otherwise affect STERIS’s performance, results, prospects or value; (e) the potential of international unrest, including military conflicts, economic downturn and effects of currency fluctuations; (f) the possibility of delays in receipt of orders, order cancellations, or the manufacture or shipment of ordered products; (g) the possibility that anticipated growth, performance or other results may not be achieved, or that timing, execution, impairments, or other issues associated with STERIS’s businesses, industry or initiatives may adversely impact STERIS’s performance, results, prospects or value; (h) the impact on STERIS and its operations of any legislation, regulations or orders, including but not limited to any new trade, regulations or orders, that may be implemented by the U.S. administration or Congress, or of any responses thereto by non-U.S. governments; (i) the possibility that anticipated financial results, anticipated revenue, productivity improvements, cost savings, growth synergies, and other anticipated benefits of acquisitions, restructuring efforts, and divestitures will not be realized or will be less than anticipated; (j) the level of STERIS’s indebtedness limiting financial flexibility or increasing future borrowing costs; (k) the effects of changes in credit availability and pricing, as well as the ability of STERIS and STERIS’s Customers and suppliers to adequately access the credit markets, on favorable terms or at all, when needed; (l) the impacts of increasing competition within our industry, which may exert pressure on our pricing strategy or lead to decreasing demand for our products and services; (m) the effects on our operations resulting from labor-related issues, such as strikes, unsuccessful union negotiations and other workforce disruptions; (n) the possibility of economic downturns and recessions, which could negatively impact our business by reducing consumer and Customer spending. Unless legally required, STERIS does not undertake to update or revise any forward-looking statements even if events make clear that any projected results, express or implied, will not be realized.

FAQ

What is STERIS's new dividend amount for 2025?

STERIS (NYSE: STE) has increased its quarterly dividend to $0.63 per share, representing a $0.06 increase from the previous dividend amount.

When will STERIS (STE) pay its next dividend?

STERIS will pay its quarterly dividend on September 26, 2025, to shareholders of record as of September 4, 2025.

How many consecutive years has STERIS increased its dividend?

STERIS has achieved 20 consecutive years of dividend growth, demonstrating a consistent track record of increasing shareholder returns.

What is STERIS's main business focus?

STERIS is a leading global provider of products and services supporting patient care, with an emphasis on infection prevention, providing innovative healthcare and life science solutions worldwide.

What are the key risks facing STERIS (STE) in 2025?

Key risks include high debt levels affecting financial flexibility, increasing competition impacting pricing, potential economic downturns, and international market uncertainties.